• Ling Ning, Lei Liu, Wenyuan Li, Hongtao Liu, Jizhou Wang, Ziqin Yao, Shengyu Zhang, Desheng Zhao, Björn Nashan, Aizong Shen, Lianxin Liu, and Lei Li.
• Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, P.R. China.
• Am. J. Transplant. 2020 Jul 1; 20 (7): 1864-1868.

AbstractAn ongoing outbreak of pneumonia associated with the severe acute respiratory coronavirus 2 (SARS-CoV-2) started in Wuhan, China, with cases now confirmed in multiple countries. The clinical course of patients remains to be fully characterized, clinical presentation ranges from asymptomatic infection to acute respiratory distress syndrome and acute renal failure, and no pharmacological therapies of proven efficacy yet exist. We report a case of SARS-CoV-2 infection in a renal transplant recipient with excellent outcome. This case states the importance of close monitoring of the concentration of cyclosporine in patients treated with lopinavir/ritonavir; the routine treatment of corticosteroid can be continued. This is a rare report of SARS-CoV-2 infection in a renal transplant recipient. Further data are needed to achieve better understanding of the impact of immunosuppressive therapy on the clinical presentation, severity, and outcome of SARS-CoV-2 infections in solid organ transplant recipients.© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.

49 keywords...

hide…